Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Feb 19, 2023 6:18pm
198 Views
Post# 35294528

RE:ASCO

RE:ASCO
I can't say for sure as I was not at this meeting but I have attended other meetings like it. The presentation is sometimes just a poster on display with the author present. Or it can be a poster and then a short presentation to go with it. In this case, the urotoday article makes it clear that they presented the same response rates as the Nov 29 company update. Which has to do with the rules on submitting the poster. Cannot add new data after a certain date in time.

My hope is that the company will release the poster on their website and that there is more detail on the trajectory of each patient to reach 450. From that we can see better the patients who were CR from 90 onwards vs some that were CR later.

I would be happy if the company does some PR off ASCO next week. Then adds more data updates at end of Feb...or an announcement about IND appliation....or an announcement about anything at all really.
<< Previous
Bullboard Posts
Next >>